Lyra Therapeutics, Inc. (LYRA) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $15.89M | -60.8% |
| 2024 | $40.58M | +81.5% |
| 2023 | $22.35M | -31.3% |
| 2022 | $32.55M | -28.8% |
| 2021 | $45.75M | -38.7% |
| 2020 | $74.59M | +660.5% |
| 2019 | $9.81M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $15.89M | -60.8% |
| 2024 | $40.58M | +81.5% |
| 2023 | $22.35M | -31.3% |
| 2022 | $32.55M | -28.8% |
| 2021 | $45.75M | -38.7% |
| 2020 | $74.59M | +660.5% |
| 2019 | $9.81M | — |